TRIA Bioscience has invented a new vaccine platform that replaces traditional conjugate vaccine technology with Epitope-Specific Nanoparticles (ESnPs). This approach eliminates chemical conjugation of weak antigens to large foreign protein carriers needed for antibody induction along with its complex vaccine manufacturing requirements. Instead, a miniaturized 70 amino acid carrier that mediates nanoparticle formation and B cell activation is assembled with the antigen of choice in a single production run by solid-phase peptide synthesis. This technology is being used for two very large global markets; substance use disorders including nicotine addiction and influenza infection. Strong preclinical proof of concept for both projects has been established and product development plans are in place. TRIA has been funded exclusively by federal grants and its technology is protected by an extensive patent portfolio.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Nicotine addiction vaccine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):